Online abortion pill sellers can continue illegally trafficking mifepristone into pro-life states until litigation over a landmark abortion drug lawsuit out of Louisiana is resolved, the Supreme Court ruled on Thursday. The high bench’s grant of mifepristone manufacturers’ emergency appeal endangers women and babies who are not required by the U.S. Food and Drug Administration to receive in-person medical care before or after obtaining abortion pills.
The 5th Circuit Court of Appeals initially paused the FDA’s mail-order abortion permissions when it unanimously granted Louisiana’s request for a stay at the beginning of May. Two days later, the Supreme Court temporarily halted the 5th Circuit’s block.
